|Daily Range||$68.59 - $68.95|
|52-Week Range||$48.97 - $70.52|
|Dividend (Yield)||$0.00 (2.4%)|
|Average Daily Volume||354,494|
|Current FY EPS||$4.07|
News & Commentary
Celldex's offering puts acquisition/partnership rumors by the likes of Roche, Amgen, or Alexion on the back burner. It also raises significant questions prior to a major data release. Does it change the outlook for the Celldex's stock?
Celldex didn't sell at the top, but the company executed a solid equity raise that should fund years of development.
With a lot of attention on high-risk programs and unlikely strategic moves, Novartis may struggle to outperform from these levels.
Mylan and Biocon gain approval for Herceptin biosimilar in India while Roche and ImmunoGen gain approval for Herceptin-DM1 combination Kadcyla in Europe.
A surprising finding published last week could open a door for statins to prevent breast cancer.
These three winners outlast a downbeat day from the S&P 500, which couldn't manage to hang on to gains despite strong manufacturing data from the PMI.
A compelling new drug in development from Merck (MRK) has a chance to change melanoma treatment, posing a threat to rapidly growing market share for Bristol Myers' (BMY) Yervoy.
Galena Biopharma has added stock gains of 65% in the last month, adding to a great 24 months, but are there still fundamental reasons to be bullish?
Drug companies continue to acquire orphan drug biotechnology companies to boost pipelines. Will BioMarin's Vimizim help convince them to buy BioMarin too?